首页> 外文期刊>Cancers >Identification of Serum Biomarkers for Biliary Tract Cancers by a Proteomic Approach Based on Time-of-Flight Mass Spectrometry
【24h】

Identification of Serum Biomarkers for Biliary Tract Cancers by a Proteomic Approach Based on Time-of-Flight Mass Spectrometry

机译:基于飞行时间质谱的蛋白质组学方法鉴定胆道癌血清生物标志物

获取原文
           

摘要

Biliary tract cancers (BTCs) are lethal malignancies currently lacking satisfactory methods for early detection and accurate diagnosis. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) is a promising diagnostic tool for this disease. In this pilot study, sera samples from 50 BTCs and 30 cholelithiasis patients as well as 30 healthy subjects from a population-based case-control study were randomly grouped into training set (30 BTCs, 20 cholelithiasis and 20 controls), duplicate of training set, and blind set (20 BTCs, 10 cholelithiasis and 10 controls); all sets were analyzed on Immobilized Metal Affinity Capture ProteinChips via SELDI-TOF-MS. A decision tree classifier was built using the training set and applied to all test sets. The classification tree constructed with the 3,400, 4,502, 5,680, 7,598, and 11,242 mass-to-charge ratio (m/z) protein peaks had a sensitivity of 96.7% and a specificity of 85.0% when comparing BTCs with non-cancers. When applied to the duplicate set, sensitivity was 66.7% and specificity was 70.0%, while in the blind set, sensitivity was 95.0% and specificity was 75.0%. Positive predictive values of the training, duplicate, and blind sets were 82.9%, 62.5% and 79.2%, respectively. The agreement of the training and duplicate sets was 71.4% (Kappa = 0.43, u = 3.98, P 0.01). The coefficient of variations based on 10 replicates of one sample for the five differential peaks were 15.8–68.8% for intensity and 0–0.05% for m/z. These pilot results suggest that serum protein profiling by SELDI-TOF-MS may be a promising approach for identifying BTCs but low assay reproducibility may limit its application in clinical practice.
机译:胆道癌(BTC)是致死性恶性肿瘤,目前缺乏早期检测和准确诊断的令人满意的方法。表面增强激光解吸/电离飞行时间质谱(SELDI-TOF-MS)是对该疾病的一种有前途的诊断工具。在这项先导研究中,将来自50个BTC和30例胆石症患者的血清样本以及来自基于人群的病例对照研究的30名健康受试者随机分组为训练集(30个BTC,20例胆石症和20个对照),重复训练集和盲目套装(20个BTC,10个胆石症和10个对照);所有组均通过SELDI-TOF-MS在固定的金属亲和捕获蛋白芯片上进行分析。使用训练集构建决策树分类器,并将其应用于所有测试集。将BTC与非癌症相比,由3400、4502、5680、7598和11242质荷比(m / z)蛋白质峰构成的分类树的灵敏度为96.7%,特异性为85.0%。当应用于重复组时,敏感性为66.7%,特异性为70.0%,而在盲组中,敏感性为95.0%,特异性为75.0%。训练组,重复组和盲组的阳性预测值分别为82.9%,62.5%和79.2%。训练集和重复集的一致性为71.4%(Kappa = 0.43,u = 3.98,P <0.01)。基于五个样本峰的一个样品的10个重复进行的变异系数,强度为15.8–68.8%,m / z为0–0.05%。这些初步结果表明,通过SELDI-TOF-MS进行血清蛋白谱分析可能是鉴定BTC的一种有前途的方法,但是低检测重复性可能会限制其在临床实践中的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号